Nippon Chemiphar Co., Ltd.
4539.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.67B
Close$
Share Statistics
| Market cap | $5.67 Billion |
|---|---|
| Enterprise Value | $17.12 Billion |
| Dividend Yield | $50.00 (3.20%) |
| Earnings per Share | $54.79 |
| Beta | 0.2 |
| Outstanding Shares | 3,624,023 |
Return
| Return on Equity | -0.64% |
|---|---|
| Return on Assets | -0.24% |
| Return on Invested Capital | -0.27% |
Valuation & Multiples
| P/E Ratio | -45.54 |
|---|---|
| PEG | 32.11 |
| Price to Sales | 0.17 |
| Price to Book Ratio | 0.29 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | -159.99 |
| Enterprise Value to Net Income | -139 |
| Total Debt to Enterprise | 1.08 |
| Debt to Equity | 0.96 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nippon Chemiphar Co., Ltd.
878 employees
CEO: Kazushiro Yamaguchi Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC ...